Lipid encapsulated cisplatin - LiPlasome Pharma

Drug Profile

Lipid encapsulated cisplatin - LiPlasome Pharma

Alternative Names: LiPlaCis

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator LiPlasome Pharma
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Jan 2017 Phase-II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in Denmark (IV) before January 2017
  • 30 Dec 2016 Lipid encapsulated cisplatin licensed to 2X Oncology
  • 30 Dec 2016 Oncology Venture in-licenses Drug Response Prediction (DRP™) technology from Medical Prognosis Institute with three year world-wide exclusivity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top